CAS 1050500-29-2

Allitinib tosylate

Description:

Allitinib tosylate is a small molecule inhibitor primarily used in the treatment of certain types of cancer, particularly non-small cell lung cancer (NSCLC) that harbor specific mutations in the epidermal growth factor receptor (EGFR). As a tosylate salt, it enhances the solubility and stability of the active compound, facilitating its pharmacological properties. The substance acts by selectively inhibiting the tyrosine kinase activity of EGFR, thereby blocking downstream signaling pathways that promote tumor growth and survival. Allitinib tosylate is characterized by its ability to penetrate cellular membranes effectively, which is crucial for its therapeutic action. Its pharmacokinetic profile includes considerations of absorption, distribution, metabolism, and excretion, which are essential for determining dosing regimens. Additionally, like many targeted therapies, it may exhibit side effects related to its mechanism of action, necessitating careful monitoring during treatment. Overall, Allitinib tosylate represents a significant advancement in targeted cancer therapy, offering a more personalized approach to treatment based on genetic profiling of tumors.

Synonyms:

• AST 1306 tosylate
• AST-1306 TsOH
• N-[4-[[3-Chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-6-quinazolinyl]-2-propenamide 4-methylbenzenesulfonate
• AST 1306 (p-Toluenesulfonic acid)

AST-1306 (tosylate)

CAS: 1050500-29-2

Formula: C₃₁H₂₆ClFN₄O₅S

Purity: 99%

Molecular weight: 621.0783

Ref: IN-DA008TDK

Allitinib tosylate

CAS: 1050500-29-2

Allitinib tosylate

Purity: ≥98%

Molecular weight: 621.08g/mol

Ref: 54-BUP09196

Allitinib tosylate

CAS: 1050500-29-2

Allitinib tosylate (AST-1306) is a novel irreversible inhibitor of EGFR and ErbB2 with IC50 of 0.5 nM and 3 nM, respectively.

Formula: C₃₁H₂₆ClFN₄O₅S

Purity: 98.46% - 98.68%

Color and Shape: Solid

Molecular weight: 621.08

Ref: TM-T6331